Insight, China's Pharmaceutical Industry

Company Drug

Ribo Life Science’s siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients

Ribo Life Science (HKG: 6938) announced that its small interfering RNA (siRNA) therapy vortosiran (BD4059)...

Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC Risvutatug Rezetecan Hits Primary Endpoint in Osteosarcoma Phase III Trial, Validating GSK Partnership

Fineline Cube Jul 29, 2026

Hansoh Pharmaceutical (HKG: 3692) announced that its pivotal Phase III ARTEMIS-011 clinical trial of Risvutatug...

Company Drug PIC

Shionogi Launches XOCOVA (Ensitrelvir) in US for COVID-19 Post-Exposure Prophylaxis Following 67% Risk Reduction in Global Trial

Fineline Cube Jul 29, 2026

Shionogi & Co., Ltd. (TYO: 4507) announced the U.S. commercial availability of XOCOVA (ensitrelvir), an...

Company Drug

Insilico Medicine’s AI-Discovered Pan-TEAD Inhibitor ISM6331 Receives FDA Fast Track Designation for Malignant Pleural Mesothelioma

Fineline Cube Jul 29, 2026

Insilico Medicine (HKG: 3696) announced that ISM6331, a novel pan-TEAD inhibitor discovered through the company’s...

Company Drug

Humanwell Healthcare’s Non-Opioid Analgesic HW243040 Receives NMPA Approval for Peripheral Neuropathic Pain Clinical Trials

Fineline Cube Jul 29, 2026

Humanwell Healthcare (SHA: 600079) announced that its novel drug candidate HW243040 has received clinical trial...

Company Deals

TPMeds Secures Tens of Millions in RMB Angel Round Led by Lotus Lake Ventures to Advance TPM004 IND and PepTetris Platform

Fineline Cube Jul 29, 2026

TPMeds announced the successful completion of an Angel financing round amounting to tens of millions...

Company Drug

AstraZeneca’s Ultomiris Fails Primary Endpoint in Adult HSCT-TMA Phase III Trial Despite Positive Pediatric Data

Fineline Cube Jul 29, 2026

AstraZeneca plc (NYSE: AZN) announced that its ALXN1210-TMA-313 Phase III clinical trial failed to meet...

Policy / Regulatory

China’s CDE Tightens Drug Review Standards with New “No Supplemental Data” Rule for Major Deficiencies

Fineline Cube Jul 29, 2026

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) released a...

Company Drug

Changchun High-Tech Industries Subsidiary GenSci Advances Graves’ Disease Therapy to Phase II with US Partner Yarrow Bioscience

Fineline Cube Jul 29, 2026

Changchun High-Tech Industries (Group) Co., Ltd. (SHE: 000661) announced that its subsidiary GenSci has initiated...

Policy / Regulatory

China’s NMPA Proposes Sweeping Reforms to Medical Device E-Commerce with New Draft Regulations

Fineline Cube Jul 29, 2026

China’s National Medical Products Administration (NMPA) released the Administrative Measures for Medical Device Online Sales...

Policy / Regulatory

China’s 12th National Drug Procurement Round Attracts 500+ Companies, Targets 7.34 Billion Units

Fineline Cube Jul 29, 2026

China’s National Drug Joint Procurement Office released enterprise-related information for the 12th batch of national...

Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026

HBM Holdings Limited (HKG: 2142) announced a strategic cooperation framework agreement with China National Pharmaceutical...

Company

Antengene Achieves Profitability with H1 2026 Revenue of RMB 490-536M Driven by Strategic Out-Licensing Deals

Fineline Cube Jul 28, 2026

Antengene Corporation Limited (HKG: 6996) announced preliminary financial results for the six months ended June...

Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Fineline Cube Jul 28, 2026

China Medical System Holdings Limited (CMS) (HKG: 0867) announced that its Southeast Asia subsidiary, Rxilient...

Company Medical Device

Broncus Medical’s BroncTru Dilation Catheter Secures CE Mark Under EU MDR for Comprehensive Lung Diagnostics and Therapy

Fineline Cube Jul 28, 2026

Broncus Medical Inc. (HKG: 2216) announced that its self-developed BroncTru disposable bronchoscopic dilation catheter has...

Company Drug

CSPC’s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor

Fineline Cube Jul 28, 2026

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the marketing application for its self-developed Class...

Company Drug

Hengrui’s Tissue Factor-Targeting ADC SHR-4375 Receives FDA Orphan Drug Designation for Pancreatic Cancer

Fineline Cube Jul 28, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its innovative antibody-drug conjugate...

Company Drug

CSPC’s Novel SNRI Ammuxetine Meets Primary Endpoint in Phase III Depression Trial, Poised for First-Line Status

Fineline Cube Jul 28, 2026

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the Phase III clinical trial of its...

Company Drug

Fosun Pharma’s DM1001 Receives NMPA Clearance for Parkinson’s Disease Clinical Trials

Fineline Cube Jul 28, 2026

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that DM1001, a chemical...

Company Drug

InnoCare’s TYK2 Inhibitor Fadeucravacitinib Hits Primary Endpoint in Phase III Psoriasis Trial

Fineline Cube Jul 28, 2026

InnoCare Pharma (HKG: 9969) announced that the pivotal Phase III clinical trial of its potent,...

Insight, China's Pharmaceutical Industry

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Ribo Life Science’s siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients

Hansoh Pharmaceutical’s B7-H3 ADC Risvutatug Rezetecan Hits Primary Endpoint in Osteosarcoma Phase III Trial, Validating GSK Partnership

Shionogi Launches XOCOVA (Ensitrelvir) in US for COVID-19 Post-Exposure Prophylaxis Following 67% Risk Reduction in Global Trial

Insilico Medicine’s AI-Discovered Pan-TEAD Inhibitor ISM6331 Receives FDA Fast Track Designation for Malignant Pleural Mesothelioma

Humanwell Healthcare’s Non-Opioid Analgesic HW243040 Receives NMPA Approval for Peripheral Neuropathic Pain Clinical Trials

TPMeds Secures Tens of Millions in RMB Angel Round Led by Lotus Lake Ventures to Advance TPM004 IND and PepTetris Platform

AstraZeneca’s Ultomiris Fails Primary Endpoint in Adult HSCT-TMA Phase III Trial Despite Positive Pediatric Data

China’s CDE Tightens Drug Review Standards with New “No Supplemental Data” Rule for Major Deficiencies

Changchun High-Tech Industries Subsidiary GenSci Advances Graves’ Disease Therapy to Phase II with US Partner Yarrow Bioscience

China’s NMPA Proposes Sweeping Reforms to Medical Device E-Commerce with New Draft Regulations

China’s 12th National Drug Procurement Round Attracts 500+ Companies, Targets 7.34 Billion Units

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Antengene Achieves Profitability with H1 2026 Revenue of RMB 490-536M Driven by Strategic Out-Licensing Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Broncus Medical’s BroncTru Dilation Catheter Secures CE Mark Under EU MDR for Comprehensive Lung Diagnostics and Therapy

CSPC’s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor

Hengrui’s Tissue Factor-Targeting ADC SHR-4375 Receives FDA Orphan Drug Designation for Pancreatic Cancer

CSPC’s Novel SNRI Ammuxetine Meets Primary Endpoint in Phase III Depression Trial, Poised for First-Line Status

Fosun Pharma’s DM1001 Receives NMPA Clearance for Parkinson’s Disease Clinical Trials

InnoCare’s TYK2 Inhibitor Fadeucravacitinib Hits Primary Endpoint in Phase III Psoriasis Trial

You Missed

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404